154 related articles for article (PubMed ID: 30383785)
21. Macrophage migration inhibitory factor regulating the expression of VEGF-C through MAPK signal pathways in breast cancer MCF-7 cell.
Zhang J; Zhang G; Yang S; Qiao J; Li T; Yang S; Hong Y
World J Surg Oncol; 2016 Feb; 14():51. PubMed ID: 26911617
[TBL] [Abstract][Full Text] [Related]
22. The critical role of macrophage migration inhibitory factor in insulin activity.
Vujicic M; Senerovic L; Nikolic I; Saksida T; Stosic-Grujicic S; Stojanovic I
Cytokine; 2014 Sep; 69(1):39-46. PubMed ID: 25022960
[TBL] [Abstract][Full Text] [Related]
23. Contribution of macrophage migration inhibitory factor to the pathogenesis of dengue virus infection.
Assunção-Miranda I; Amaral FA; Bozza FA; Fagundes CT; Sousa LP; Souza DG; Pacheco P; Barbosa-Lima G; Gomes RN; Bozza PT; Da Poian AT; Teixeira MM; Bozza MT
FASEB J; 2010 Jan; 24(1):218-28. PubMed ID: 19776337
[TBL] [Abstract][Full Text] [Related]
24. Role of macrophage migration inhibitory factor in primary glioblastoma multiforme cells.
Baron N; Deuster O; Noelker C; Stüer C; Strik H; Schaller C; Dodel R; Meyer B; Bacher M
J Neurosci Res; 2011 May; 89(5):711-7. PubMed ID: 21360573
[TBL] [Abstract][Full Text] [Related]
25. PEGylated long-circulating liposomes deliver homoharringtonine to suppress multiple myeloma cancer stem cells.
Li M; Shi F; Fei X; Wu S; Wu D; Pan M; Luo S; Gu N; Dou J
Exp Biol Med (Maywood); 2017 May; 242(9):996-1004. PubMed ID: 28056549
[TBL] [Abstract][Full Text] [Related]
26. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
27. Macrophage migration inhibitory factor promotes osteosarcoma growth and lung metastasis through activating the RAS/MAPK pathway.
Wang C; Zhou X; Li W; Li M; Tu T; Ba X; Wu Y; Huang Z; Fan G; Zhou G; Wu S; Zhao J; Zhang J; Chen J
Cancer Lett; 2017 Sep; 403():271-279. PubMed ID: 28642171
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of macrophage migration inhibitory factor-induced decrease of T-type Ca(2+) channel current in atrium-derived cells.
Rao F; Deng CY; Wu SL; Xiao DZ; Huang W; Deng H; Kuang SJ; Lin QX; Shan ZX; Liu XY; Zhu JN; Yu XY
Exp Physiol; 2013 Jan; 98(1):172-82. PubMed ID: 22848081
[TBL] [Abstract][Full Text] [Related]
29. USO1 promotes tumor progression via activating Erk pathway in multiple myeloma cells.
Jin Y; Dai Z
Biomed Pharmacother; 2016 Mar; 78():264-271. PubMed ID: 26898451
[TBL] [Abstract][Full Text] [Related]
30. Macrophage migration inhibitory factor promotes expression of GLUT4 glucose transporter through MEF2 and Zac1 in cardiomyocytes.
Liang Y; Yuan W; Zhu W; Zhu J; Lin Q; Zou X; Deng C; Fu Y; Zheng X; Yang M; Wu S; Yu X; Shan Z
Metabolism; 2015 Dec; 64(12):1682-93. PubMed ID: 26455966
[TBL] [Abstract][Full Text] [Related]
31. Macrophage migration inhibitory factor as a potential prognostic factor in gastric cancer.
He LJ; Xie D; Hu PJ; Liao YJ; Deng HX; Kung HF; Zhu SL
World J Gastroenterol; 2015 Sep; 21(34):9916-26. PubMed ID: 26379396
[TBL] [Abstract][Full Text] [Related]
32. 4-IPP, a selective MIF inhibitor, causes mitotic catastrophe in thyroid carcinomas.
Varinelli L; Caccia D; Volpi CC; Caccia C; De Bortoli M; Taverna E; Gualeni AV; Leoni V; Gloghini A; Manenti G; Bongarzone I
Endocr Relat Cancer; 2015 Oct; 22(5):759-75. PubMed ID: 26206776
[TBL] [Abstract][Full Text] [Related]
33. Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
Franqui-Machin R; Wendlandt EB; Janz S; Zhan F; Tricot G
Oncotarget; 2015 Dec; 6(38):40496-506. PubMed ID: 26415231
[TBL] [Abstract][Full Text] [Related]
34. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
[TBL] [Abstract][Full Text] [Related]
35. Macrophage migration inhibitory factor - a therapeutic target in gallbladder cancer.
Subbannayya T; Leal-Rojas P; Barbhuiya MA; Raja R; Renuse S; Sathe G; Pinto SM; Syed N; Nanjappa V; Patil AH; Garcia P; Sahasrabuddhe NA; Nair B; Guerrero-Preston R; Navani S; Tiwari PK; Santosh V; Sidransky D; Prasad TS; Gowda H; Roa JC; Pandey A; Chatterjee A
BMC Cancer; 2015 Nov; 15():843. PubMed ID: 26530123
[TBL] [Abstract][Full Text] [Related]
36. Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination.
Akhmetzyanova I; McCarron MJ; Parekh S; Chesi M; Bergsagel PL; Fooksman DR
Leukemia; 2020 Jan; 34(1):245-256. PubMed ID: 31439945
[TBL] [Abstract][Full Text] [Related]
37. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
Kim D; Park CY; Medeiros BC; Weissman IL
Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
[TBL] [Abstract][Full Text] [Related]
38. Role of MIF in inflammation and tumorigenesis.
Bach JP; Rinn B; Meyer B; Dodel R; Bacher M
Oncology; 2008; 75(3-4):127-33. PubMed ID: 18791328
[TBL] [Abstract][Full Text] [Related]
39. Macrophage migration inhibitory factor counterregulates dexamethasone-mediated suppression of hypoxia-inducible factor-1 alpha function and differentially influences human CD4+ T cell proliferation under hypoxia.
Gaber T; Schellmann S; Erekul KB; Fangradt M; Tykwinska K; Hahne M; Maschmeyer P; Wagegg M; Stahn C; Kolar P; Dziurla R; Löhning M; Burmester GR; Buttgereit F
J Immunol; 2011 Jan; 186(2):764-74. PubMed ID: 21169549
[TBL] [Abstract][Full Text] [Related]
40. MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma.
Wang Q; Zhao D; Xian M; Wang Z; Bi E; Su P; Qian J; Ma X; Yang M; Liu L; Zu Y; Pingali SR; Chen K; Cai Z; Yi Q
Blood; 2020 Nov; 136(22):2557-2573. PubMed ID: 32582913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
